NCT05516966View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

May 24, 2023

Study Completion Date

May 24, 2023

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

HRS9531

Administrated SC

DRUG

Placebo

Administrated SC

DRUG

Dulaglutide Injection

Administrated SC

Trial Locations (1)

200000

Zhongshan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY